Skip to main content
Erschienen in: Supportive Care in Cancer 12/2019

10.04.2019 | Original Article

Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey

verfasst von: Whitney E. Zahnd, Melinda M. Davis, Jason S. Rotter, Robin C. Vanderpool, Cynthia K. Perry, Jackilen Shannon, Linda K. Ko, Stephanie B. Wheeler, Cassie L. Odahowski, Paige E. Farris, Jan M. Eberth

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Rural cancer survivors may disproportionately experience financial problems due to their cancer because of greater travel costs, higher uninsured/underinsured rates, and other factors compared to their urban counterparts. Our objective was to examine rural-urban differences in reported financial problems due to cancer using a nationally representative survey.

Methods

We used data from three iterations of the National Cancer Institute’s Health Information and National Trends Survey (2012, 2014, and 2017) to identify participants who had a previous or current cancer diagnosis. Our outcome of interest was self-reported financial problems associated with cancer diagnosis and treatment. Rural-urban status was defined using 2003 Rural-Urban Continuum Codes. We calculated weighted percentages and Wald chi-square statistics to assess rural-urban differences in demographic and cancer characteristics. In multivariable logistic regression models, we examined the association between rural-urban status and other factors and financial problems, reporting the corresponding adjusted predicted probabilities.

Findings

Our sample included 1359 cancer survivors. Rural cancer survivors were more likely to be married, retired, and live in the Midwest or South. Over half (50.5%) of rural cancer survivors reported financial problems due to cancer compared to 38.8% of urban survivors (p = 0.02). This difference was attenuated in multivariable models, 49.3 and 38.7% in rural and urban survivors, respectively (p = 0.06).

Conclusions

A higher proportion of rural survivors reported financial problems associated with their cancer diagnosis and treatment compared to urban survivors. Future research should aim to elucidate these disparities and interventions should be tested to address the cancer-related financial problems experienced by rural survivors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Yabroff KR, Zhao J, Zheng Z, Rai A, Han X (2018) Medical financial hardship among cancer survivors in the United States: what do we know? What do we need to know? Cancer Epidemiol Biomark Prev 27:1389–1397CrossRef Yabroff KR, Zhao J, Zheng Z, Rai A, Han X (2018) Medical financial hardship among cancer survivors in the United States: what do we know? What do we need to know? Cancer Epidemiol Biomark Prev 27:1389–1397CrossRef
8.
Zurück zum Zitat Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P (2015) Challenges of rural cancer care in the United States. Oncology (Williston Park) 29(9):633–640 Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P (2015) Challenges of rural cancer care in the United States. Oncology (Williston Park) 29(9):633–640
10.
Zurück zum Zitat Mathews M, West R, Buehler S (2009) How important are out-of-pocket costs to rural patients’ cancer care decisions? Can J Rural Med 14(2):54–60PubMed Mathews M, West R, Buehler S (2009) How important are out-of-pocket costs to rural patients’ cancer care decisions? Can J Rural Med 14(2):54–60PubMed
11.
Zurück zum Zitat Whitney RL, Bell JF, Reed SC, Lash R, Bold RJ, Kim KK et al (2016) Predictors of financial difficulties and work modifications among cancer survivors in the United States. J Cancer Surviv 10(2):241–250CrossRefPubMed Whitney RL, Bell JF, Reed SC, Lash R, Bold RJ, Kim KK et al (2016) Predictors of financial difficulties and work modifications among cancer survivors in the United States. J Cancer Surviv 10(2):241–250CrossRefPubMed
16.
Zurück zum Zitat Greenberg AJ, Haney D, Blake KD, Moser RP, Hesse BW (2018) Differences in access to and use of electronic personal health information between rural and urban residents in the United States. J Rural Health 34 Suppl 1:s30-s8 doi 10.1111/jrh.12228:s30–s38CrossRefPubMed Greenberg AJ, Haney D, Blake KD, Moser RP, Hesse BW (2018) Differences in access to and use of electronic personal health information between rural and urban residents in the United States. J Rural Health 34 Suppl 1:s30-s8 doi 10.1111/jrh.12228:s30–s38CrossRefPubMed
20.
21.
Zurück zum Zitat SAS Institute Inc. (2009) SAS/STAT ® 9.2 User’s Guide SEC. SAS Institute Inc, NC, p 2018 SAS Institute Inc. (2009) SAS/STAT ® 9.2 User’s Guide SEC. SAS Institute Inc, NC, p 2018
22.
Zurück zum Zitat Probst JC, Moore CG, Glover SH, Samuels ME (2004) Person and place: the compounding effects of race/ethnicity and rurality on health. Am J Public Health 94(10):1695–1703CrossRefPubMedPubMedCentral Probst JC, Moore CG, Glover SH, Samuels ME (2004) Person and place: the compounding effects of race/ethnicity and rurality on health. Am J Public Health 94(10):1695–1703CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S et al (2018) Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 14:e122–e129CrossRefPubMed Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S et al (2018) Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 14:e122–e129CrossRefPubMed
27.
Zurück zum Zitat Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY (2017) The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm 23:407–411PubMed Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY (2017) The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm 23:407–411PubMed
28.
Zurück zum Zitat Zafar SY, Chino F, Ubel PA, Rushing C, Samsa G, Altomare I et al (2015) The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care 21(9):607–615PubMed Zafar SY, Chino F, Ubel PA, Rushing C, Samsa G, Altomare I et al (2015) The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care 21(9):607–615PubMed
35.
Zurück zum Zitat Shih YT, Smielauskas F, Geynisman DM, Kelly RJ, Smith TJ (2015) Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol 33(19):2190–2196CrossRefPubMedPubMedCentral Shih YT, Smielauskas F, Geynisman DM, Kelly RJ, Smith TJ (2015) Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol 33(19):2190–2196CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6(9):166CrossRefPubMedPubMedCentral Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6(9):166CrossRefPubMedPubMedCentral
Metadaten
Titel
Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey
verfasst von
Whitney E. Zahnd
Melinda M. Davis
Jason S. Rotter
Robin C. Vanderpool
Cynthia K. Perry
Jackilen Shannon
Linda K. Ko
Stephanie B. Wheeler
Cassie L. Odahowski
Paige E. Farris
Jan M. Eberth
Publikationsdatum
10.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04742-z

Weitere Artikel der Ausgabe 12/2019

Supportive Care in Cancer 12/2019 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.